Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Nuwiq

Phase 3Biologic

Nuwiq is one of 5 biologic programs targeting Haemophilia A. It is currently in Phase 3.

1

Indications

4

Total Trials

3

Active Trials

4

Competitors

Pipeline

Status by Indication[3][1]

Indication

Haemophilia aRecruiting

Haemophilia aPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Haemophilia a

#DrugCompanyPhaseTrials

ALHEMO

Efanesoctocog Alfa

Mim8

Nuwiq

NNC0442-0344 a

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Haemophilia a

NCT05936580

Q2 2029

Hemophilia a

NCT04023019

Clinical

Trials by Indication[1]

Haemophilia A2 trials

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Recruiting· Octapharma logo

Octapharma·Phase 4·NCT05935358·28 enrolled

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Recruiting· Octapharma logo

Octapharma·Phase 4·NCT05936580·28 enrolled

Hemophilia A1 trial

Treatment of Hemophilia A Patients With FVIII Inhibitors

Recruiting·EEmory University··NCT04023019·120 enrolled

Unspecified1 trial

Emicizumab PUPs and Nuwiq ITI Study

Withdrawn·EEmory University·Phase 3·NCT04030052

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Nuwiq. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nuwiq compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nuwiq. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Octapharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Octapharma

Related News